paeonol has been researched along with Cardiotoxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| De, D; Ding, M; Du, Y; Fu, F; Li, M; Li, Z; Shi, R | 1 |
| Cao, H; Guo, R; Jiang, W; Kong, F; Li, J; Sun, D; Wu, J; Xue, X; Zhang, B | 1 |
2 other study(ies) available for paeonol and Cardiotoxicity
| Article | Year |
|---|---|
Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCĪµ-Stat3 pathway.
Topics: Animals; Cardiotoxicity; Doxorubicin; Hydrolases; Mitochondrial Dynamics; Molecular Docking Simulation; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley | 2023 |
Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.
Topics: Acetophenones; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epirubicin; Female; Humans; Immunohistochemistry; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Inbred BALB C; Microscopy, Fluorescence; Mitogen-Activated Protein Kinases; Tumor Burden | 2016 |